Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028689 | 0.89 | MEN1 (0.43) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL8912197 | 0.86 | KMT2A (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL8912207 | 0.85 | MEN1 (0.38) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL5121809 | 0.84 | GSK3A (0.40) | MEN1KMT2AMAPTALDH1A1GSK3A | |
| SCHEMBL8849464 | 0.83 | MEN1 (0.37) | MEN1KMT2AMAPTALDH1A1POLB | |
| Ethyl Bromo Acetate SCHEMBL30029142 | 0.82 | ALDH1A1 (0.47) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Ethyl Bromo Acetate SCHEMBL30029347 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Ethyl Bromo Acetate SCHEMBL30028633 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL1693069 | 0.79 | MEN1 (0.46) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL8712493 | 0.79 | MEN1 (0.46) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105086334-A | Composite environment friendly flame retardant for ABS | YANTAI SHUNLONG CHEMICAL TECHNOLOGY CO LTD | 2015-11-25 | — | — | CN | disclosed |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | disclosed |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | disclosed |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | disclosed |
| US-20070299260-A1 | Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters | CILAG LTD. (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299260-A1 | Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters | CILAG LTD. (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299260-A1 | Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters | CILAG LTD. (CH) | 2007-12-27 | — | — | US | disclosed |
| EP-1819705-A1 | METHOD FOR PREPARING HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H-CHINOLIZIN-3(4H)-ONE ESTERS | Cilag Ltd. (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007072506-A2 | POLYMORPHIC FORMS OF DOLASETRON MESYLATE AND PROCESSES THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072507-A2 | POLYMORPHIC FORMS OF DOLASETRON BASE AND PROCESSES OF PREPARING DOLASETRON BASE, ITS POLYMORPHIC FORMS AND SALT THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
| US-5011846-A | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-30 | — | — | US | disclosed |
| US-4906755-A | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0330788-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330824-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0329903-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329904-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329905-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329902-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329932-A2 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments | MERRELL PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0266730-A1 | Esters of hexadydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | CYP4A11, CYP3A43, VKORC1 | MEN1 2584/4885KMT2A 3853/4885MAPT 4200/4885 |
| US-20070299260-A1 | Method for Preparing Hexahydro-8-Hydroxy-2, 6-Methano-2H-Chinolizin-3 (4H) -One Esters | CYP4Z1, HDHD5, HCAR2 | MEN1 2258/4885KMT2A 1047/4885MAPT 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.